Replies to post #166826 on Biotech Values

[DewDiligence]

Thanks. ABBV/ENTA's 2013 AASLD lineup of phase-2 data is consistent with the statement in #msg-92226409.

That the top-line phase-3 data will be reported via PRs on unknown dates rather than via presentation at AASLD makes it tough for people who are buying and selling options. Glad that's not my problem!